Dr Reddy’s to distribute Takeda’s dengue vaccine in India

Dr Reddy’s Laboratories has entered into a partnership with Takeda Pharmaceutical to market and distribute the Qdenga dengue vaccine in India, according to a recent announcement. This agreement comes in the wake of India's drug regulatory authority granting approval for the use of Qdenga in both children and adults. This marks a significant milestone, as it is the first dengue vaccine to receive clearance in the country.

Dr Reddy’s anticipates that the vaccine will be accessible to the Indian market in the first half of 2027. Dengue, a mosquito-borne viral infection, is experiencing rapid growth as a vector-borne disease worldwide. The World Health Organization reported that there were 14.4 million cases and 11,201 deaths globally in 2024, with India alone recording 232,425 cases and 233 deaths.

Qdenga is administered through two 0.5 ml doses, spaced three months apart. A key feature of this vaccine is that it can be used regardless of prior dengue infection, eliminating the need for pre-vaccination screening. This report, produced with AI assistance and reviewed by a human editor, provides a detailed account of this development.